Manifestation of acute appendicitis as known but paradox visceral side effect of ulcerative colitis anti-inflammatory therapy with januskinase-inhibitor Tofacitinib (Xeljanz™)-Reference-Cited by-同舟云学术

Manifestation of acute appendicitis as known but paradox visceral side effect of ulcerative colitis anti-inflammatory therapy with januskinase-inhibitor Tofacitinib (Xeljanz™)

Published:2023-08 Issue: Volume:248 Page:154333
ISSN:0344-0338
Container-title:Pathology - Research and Practice
language:en
Short-container-title:Pathology - Research and Practice

Author:

Weber F.,Eger K.I.,March C.,Croner R.S.,Meyer F.

Publisher

Elsevier BV

Subject

Cell Biology,Pathology and Forensic Medicine

Reference9 articles.

1. Recommendations on treatment of acute appendicitis: recommendations of an expert group based on the current literature;Andric;Der Chirurg.,2020

2. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience;D’Amico;Ther. Adv. Gastroenterol.,2019

3. Fachinfo Xeljanz® 5 mg/ 10 mg Filmtabletten. https://www.pfizer.de/sites/default/files/FI-16033.pdf (Accessed 29 November 2021).

4. Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies;Panés;J. Crohns Colitis,2018

5. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials;Sandborn;Clin. Gastroenterol. Hepatol.,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofacitinib Citrate Coordination‐Based Dual‐Responsive/Scavenge Nanoplatform Toward Regulate Colonic Inflammatory Microenvironment for Relieving Colitis;Advanced Healthcare Materials;2024-08-23

2. Natural approaches for the management of ulcerative colitis: evidence of preclinical and clinical investigations;Natural Products and Bioprospecting;2024-07-30

3. Tofacitinib;Reactions Weekly;2023-09-09